Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028932 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
A Phase 2 study of Ovarian Carcinoma, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06028932 is a Phase 2 study of Ovarian Carcinoma that is active but no longer recruiting, run by Yale University. The registered enrollment target is 20 participants, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06028932, a Phase 2 study of Ovarian Carcinoma, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
Study Locations (1)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06028932
The ClinicalTrials.gov registry entry for NCT06028932 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab govitecan is the first listed.
NCT06028932 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06028932 about?
NCT06028932 is a clinical study titled "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients". This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
What is the current status of trial NCT06028932?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-01-08. Estimated completion is 2027-11-01.
What conditions does trial NCT06028932 study?
This clinical trial studies the following conditions: Ovarian Carcinoma.
What interventions are being tested in trial NCT06028932?
The interventions under investigation include: Sacituzumab govitecan (DRUG).
Who is sponsoring clinical trial NCT06028932?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028932 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.